NCT00785694View on ClinicalTrials.gov

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Bladder Cancer
Interventions
DRUG

hexaminolevulinate

Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.

Trial Locations (1)

78457

GE Healthcare Medical Diagnostics, Vélizy-Villacoublay

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY

NCT00785694 - Recurrence of Bladder Cancer After Transurethral Resection With Hexvix | Biotech Hunter | Biotech Hunter